Natera Raises Sales Outlook By $140 Million — And Increases Research And Marketing Budgets
Oncology test volume grew 60.9% from a year earlier, while the quarterly net loss narrowed and annual cash flow is still forecast positive.
Natera, which runs blood-based genetic tests for cancer, women's health and organ health, raised its 2026 revenue forecast by $140 million at the midpoint Thursday, while also lifting its research and selling budgets. The company now expects sales of $3.005 billion–$3.035 billion, against $2.850 billion–$2.910 billion previously, according to the earnings announcement accompanying its SEC filing.
Oncology Leads The Test Growth
Third-quarter unaudited revenue of $794.0 million represented 34.1% reported growth from $592.2 million a year earlier. Excluding adjustments to revenue estimates for earlier tests, growth was about 42%; Natera attributed the sales increase to higher test volume and better average selling prices.
Oncology volume rose 60.9% to approximately 339,500 tests from approximately 211,000. Across the business, Natera processed approximately 1,093,100 tests, up 22.3% from approximately 893,600. Revenue was recognized on approximately 1,024,800 tests whose results reached customers during the quarter, compared with approximately 832,900 a year earlier.
NTRA shares plunged about 14% to $314.05 in Friday trading. The higher sales outlook came with higher spending forecasts.
Natera's cancer business includes Signatera, which monitors residual cancer after treatment. Its other offerings include Panorama prenatal testing, carrier and hereditary cancer screening, transplant-rejection tests and genetic testing for chronic kidney disease. The Austin, Texas-based company processed about 3.5 million tests in 2025 and reported revenue of $2,306.1 million that year.
Smaller Loss, Higher Spending
Natera's net loss narrowed to $59.9 million, or $0.42 per diluted share, from $87.5 million, or $0.64 per diluted share, a year earlier. The operating loss fell to $68.3 million from $97.6 million; weighted-average shares rose to 144.1 million from 137.2 million.
Research, development, selling and administrative expenses increased 19.5% to $576.1 million from $482.0 million. Natera attributed the increase primarily to hiring for new products and more clinical-trial spending.
The annual research budget now stands at $825 million–$925 million, versus $800 million–$900 million previously. Planned selling and administrative spending rose to $1.225 billion–$1.300 billion from $1.125 billion–$1.225 billion, with one-time expenses and faster Signatera marketing behind the change. Research priorities include the FIND screening study, residual-cancer trials and pharmaceutical investment.
Reported gross margin was 64.7%, versus 64.9% a year earlier. Revenue-estimate adjustments contributed $32.3 million in the latest quarter, compared with $55.1 million a year earlier. Excluding those adjustments, gross margin reached 63.2%, compared with 61.8% in the second quarter.
Cash And The $6 Billion Target
Natera kept its annual gross-margin forecast at 64%–66% and continued to forecast positive cash flow. Cash, cash equivalents and restricted cash increased approximately $5.7 million from the second quarter, reaching approximately $1,097.2 million at September 30, 2026, compared with $1,076.1 million at the end of 2025. Outstanding debt, including accrued interest on its UBS credit line, was $80.3 million.
Management's longer-term revenue target is $6 billion annually in 2029. Natera identifies oncology volume and pricing, international expansion including Japan, pharmaceutical services and data licensing as growth drivers, alongside women's health, organ health and rare disease.
Pharmaceutical revenue, covering testing and trial services plus data licensing across oncology and organ health, reached $63 million in the first nine months of 2026, compared with $36 million for all of 2025.
Natera's revised plan pairs a higher sales forecast with larger investment budgets—and still targets positive cash flow for 2026.
Sources
- 8-K Filing — Natera, Inc. (NTRA) — SEC EDGAR
- Exhibit ntra-20260930xex991.htm — Natera, Inc. 8-K exhibit — SEC EDGAR
- Exhibit ntra-20260930xex992.htm — Natera, Inc. 8-K exhibit — SEC EDGAR
- Natera Inc (NTRA) Q3 2026 Earnings Call Highlights: Revenue Jumps 34% as Guidance Raised Above ... — Yahoo Finance
- Natera: Q3 Earnings Snapshot — Associated Press
- Natera: Q3 Earnings Snapshot – WTOP News — wtop.com
- Natera Reports Third Quarter 2026 Financial Results — businesswire.com